Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Surgi-Vision Founder Zerhouni Nominated For NIH Directorship

This article was originally published in The Gray Sheet

Executive Summary

Johns Hopkins University School of Medicine radiologist and Vice Dean Elias Zerhouni, MD, President Bush's choice to head the National Institutes of Health, helped found a medical technology company and has strong ties to the federal agency he has been asked by the administration to lead

You may also be interested in...



Radiologist Zerhouni Ready To Take Reins At NIH; Six More Chiefs In Waiting

Elias Zerhouni, MD, will target as one of his first priorities as National Institutes of Health director the recruitment of individuals to fill leadership spots at several NIH institutes and centers

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel